Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined

Eveline A. M. Heijnsdijk*, Ellen Warner, Fiona J. Gilbert, Madeleine M. A. Tilanus-Linthorst, Gareth Evans, Petrina A. Causer, Rosalind A. Eeles, Reinie Kaas, Gerrit Draisma, Elizabeth A. Ramsay, Ruth M. L. Warren, Kimberly A. Hill, Nicoline Hoogerbrugge, Martin N. J. M. Wasser, Elisabeth Bergers, Jan C. Oosterwijk, Maartje J. Hooning, Emiel J. T. Rutgers, Jan G. M. Klijn, Don B. PlewesMartin O. Leach, Harry J. de Koning

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

64 Citaten (Scopus)

Samenvatting

Background: It is recommended that BRCA1/2 mutation carriers undergo breast cancer screening using MRI because of their very high cancer risk and the high sensitivity of MRI in detecting invasive cancers. Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines.

Methods: Three studies of mutation carriers using annual MRI and mammography were analyzed. Separate natural history models for BRCA1 and BRCA2 were calibrated to the results of these studies and used to predict the impact of various screening protocols on detection characteristics and mortality.

Results: BRCA1/2 mutation carriers (N = 1,275) participated in the studies and 124 cancers (99 invasive) were diagnosed. Cancers detected in BRCA2 mutation carriers were smaller [80% ductal carcinoma in situ (DCIS) or

Conclusions: Our studies suggest substantial mortality benefits in using MRI to screen BRCA1/2 mutation carriers aged 25 to 60 years but show important clinical differences in natural history.

Impact: BRCA1 and BRCA2 mutation carriers may benefit from different screening protocols, for example, below the age of 40. Cancer Epidemiol Biomarkers Prev; 21(9); 1458-68. (C) 2012 AACR.

Originele taal-2English
Pagina's (van-tot)1458-1468
Aantal pagina's11
TijdschriftCANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume21
Nummer van het tijdschrift9
DOI's
StatusPublished - sep-2012

Citeer dit